Sun Pharma Advanced Research Company (SPARC) Q2 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved and released.

• The company and its subsidiaries continue to operate as a going concern, supported by a promoter group entity.

Financial highlights

• Standalone revenue from operations for Q2 FY26 was ₹786 lakhs, down from ₹1,286 lakhs in Q2 FY25; half-year revenue was ₹1,750 lakhs, down from ₹2,967 lakhs year-over-year.

• Standalone net loss for Q2 FY26 was ₹7,597 lakhs, compared to a net loss of ₹10,769 lakhs in Q2 FY25; half-year net loss was ₹12,800 lakhs, compared to ₹20,453 lakhs year-over-year.

• Consolidated revenue from operations for Q2 FY26 was ₹786 lakhs, with a consolidated net loss of ₹7,579 lakhs; half-year consolidated net loss was ₹12,760 lakhs.

• Total expenses for the half year were ₹15,453 lakhs (standalone) and ₹15,425 lakhs (consolidated), both lower than the prior year.

Outlook and guidance

• The company and group continue to report cash losses but maintain going concern status due to support from the promoter group.